Phenylpropanolamine

Verify with FDA CVM →

803 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
803
Total Reports
120
Deaths Reported
1490.0%
Death Rate

Active Ingredients

Phenylpropanolamine

Administration Routes

OralUnknownTopicalParenteral

Species Affected

Dog 793
Human 6
Unknown 4

Most Affected Breeds

Retriever - Labrador 115
Crossbred Canine/dog 99
Shepherd Dog - German 45
Boxer (German Boxer) 33
Terrier - Yorkshire 21
Doberman Pinscher 21
Dog (unknown) 17
Terrier - Bull - American Pit 17
Mixed (Dog) 16
Collie - Border 15

Most Reported Reactions

Vomiting 153
Lethargy (see also Central nervous system depression in 'Neurological') 130
Accidental exposure 90
Death by euthanasia 82
Diarrhoea 79
Anorexia 73
Emesis 69
Agitation 65
Elevated alanine aminotransferase (ALT) 55
Panting 48
Ataxia 45
Urinary incontinence 43

Outcome Breakdown

Recovered/Normal
281 (36.0%)
Ongoing
216 (27.7%)
Outcome Unknown
158 (20.2%)
Euthanized
76 (9.7%)
Died
45 (5.8%)
Recovered with Sequela
5 (0.6%)

Data Summary

Metric Value
Total adverse event reports 803
Reports involving death 120
Case-fatality rate (reported events) 1490.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Phenylpropanolamine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 803 adverse event reports referencing Phenylpropanolamine, including 120 reports in which the animal died — a 1490.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Phenylpropanolamine. Reported administration routes include Oral, Unknown, Topical, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Phenylpropanolamine reports are Dog (793 reports), Human (6 reports), Unknown (4 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (115), Crossbred Canine/dog (99), Shepherd Dog - German (45) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Phenylpropanolamine are Vomiting (153), Lethargy (see also Central nervous system depression in 'Neurological') (130), Accidental exposure (90), Death by euthanasia (82). Of the 781 reports with a coded outcome, Recovered/Normal is the leading category at 36.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Phenylpropanolamine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial